Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Progressive Corp (PGR) Price & Performance

Heron Therapeutics IncTrade
Progressive CorpTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Progressive Corp — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Progressive Corp trades at $212.5 (market cap $124.38B). The key difference: Progressive Corp is far larger — about 1961.5× Heron Therapeutics Inc's market cap, and Progressive Corp pays a 6.5% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXPGR
Market Cap
$63.41M$124.38B
Sector
HealthFinancials
52-Week High
$1.49$252.68
52-Week Low
$0.32$190.40
Enterprise Value
$161.31M$132.59B
Dividend Yield
6.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Progressive Corp

Progressive (PGR) trades at $215.33, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates robust revenue growth, rising from $49.6B in 2022 to $87.6B in 2025, with net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 EPS, though Q1 2026 slightly missed. The current P/E ratio of 10.8 suggests reasonable valuation relative to earnings strength.

The outlook for PGR remains positive with a consensus price target of $231.20, indicating potential upside. Key opportunities include expanding bundled insurance offerings and solid profitability metrics like 34.94% ROE. Risks involve competitive pressures in auto insurance and potential margin compression from growth investments. Analyst sentiment is mixed with 36.59% buy ratings, reflecting cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR